Phase I modular study of AZD6738, a novel oral, potent and...

European Journal of Cancer 2016 / 12 Vol. 69

Phase I modular study of AZD6738, a novel oral, potent and selective ataxia telangiectasia Rad3-related (ATR) inhibitor in combination (combo) with carboplatin, olaparib or durvalumab in patients (pts) with advanced cancers

Yap, T.A., Krebs, M.G., Postel-Vinay, S., Bang, Y.J., El-Khoueiry, A., Abida, W., Harrington, K., Sundar, R., Carter, L., Castanon-Alvarez, E., Im, S.A., Berges, A., Khan, M., Stephens, C., Ross, G.,
How much do you like this book?
What’s the quality of the file?
Download the book for quality assessment
What’s the quality of the downloaded files?
Volume:
69
Language:
english
Journal:
European Journal of Cancer
DOI:
10.1016/S0959-8049(16)32607-7
Date:
December, 2016
File:
PDF, 48 KB
english, 2016
Conversion to is in progress
Conversion to is failed